Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MNT002
MIFTS: 57

Mental Depression

Categories: Mental diseases, Neuronal diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Mental Depression

About this section

MalaCards integrated aliases for Mental Depression:

Name: Mental Depression 12 15 71
Depressive Disorder 71
Depression 43

Classifications:

MalaCards categories:
Anatomical: Mental diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:1596
MeSH 43 D003863
NCIt 49 C2982
SNOMED-CT 67 41006004
ICD10 32 F32.9 F33.9
UMLS 71 C0011570 C0011581
Sources

Summaries for Mental Depression

About this section
MalaCards based summary : Mental Depression, also known as depressive disorder, is related to major depressive disorder and postpartum depression, and has symptoms including dejection emotional, depressed reaction and depression aggravated. An important gene associated with Mental Depression is DCTN1 (Dynactin Subunit 1), and among its related pathways/superpathways are cAMP signaling pathway and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Valsartan and Reboxetine have been mentioned in the context of this disorder. Affiliated tissues include brain, heart and testes, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Sources

Related Diseases for Mental Depression

About this section

Diseases related to Mental Depression via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2252)
# Related Disease Score Top Affiliating Genes
1 major depressive disorder 35.0 SLC6A4 POMC OXT MAOA HTR2C HTR2A
2 postpartum depression 34.7 SLC6A4 OXT MAOA LIPA HTR1A CRH
3 atypical depressive disorder 34.4 SLC6A4 SERPINA3 POMC MAOA HTR2C HTR2A
4 bipolar disorder 34.1 SLC6A4 PRODH MAOA HTR2C HTR2A HTR1A
5 neurotic disorder 33.8 SLC6A4 MAOA HTR2A HTR1A BDNF
6 schizoaffective disorder 33.3 SLC6A4 PRODH HTR2A HTR1A COMT BDNF
7 depression 33.2 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
8 fibromyalgia 33.1 SLC6A4 POMC HTR2A CRH COMT BDNF
9 dysthymic disorder 33.1 WASF1 SLC6A4 MAOA LIPA HTR2A HTR1A
10 melancholia 33.1 SLC6A4 POMC MAOA HTR2A HTR1A CRH
11 anxiety 33.0 SLC6A4 PRODH POMC OXT MAOA HTR2C
12 eating disorder 33.0 SLC6A4 POMC HTR2C HTR2A CRH COMT
13 sleep apnea 33.0 SLC6A4 HTR2C HTR2A BDNF
14 dementia 32.9 SERPINA3 MAOA HTR2A HTR1A COMT BDNF
15 restless legs syndrome 32.9 SLC6A4 POMC MAOA COMT
16 asperger syndrome 32.9 SLC6A4 OXT COMT BDNF
17 mood disorder 32.9 SLC6A4 PRODH POMC MAOA HTR2C HTR2A
18 body dysmorphic disorder 32.9 SLC6A4 MAOA HTR2A
19 supranuclear palsy, progressive, 1 32.8 SERPINA3 MIR9-1 DCTN1
20 gilles de la tourette syndrome 32.8 SLC6A4 MAOA HTR2A HTR1A COMT BDNF
21 bipolar i disorder 32.8 SLC6A4 HTR2C HTR2A HTR1A COMT BDNF
22 schizotypal personality disorder 32.8 WASF1 PRODH COMT
23 alcohol use disorder 32.8 WASF1 SLC6A4 PRODH HTR2C HTR2A HTR1A
24 borderline personality disorder 32.7 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
25 migraine with or without aura 1 32.6 SLC6A4 POMC OXT MAOA HTR2C HTR2A
26 obsessive-compulsive disorder 32.5 SLC6A4 POMC OXT MAOA HTR2C HTR2A
27 parkinson disease, late-onset 32.5 SLC6A4 SERPINA3 PRODH MIRLET7D MIR9-1 MAOA
28 bulimia nervosa 32.4 SLC6A4 POMC OXT MAOA HTR2C HTR2A
29 schizophrenia 32.4 SLC6A4 SERPINA3 PRODH POMC OXT MIR9-1
30 autism spectrum disorder 32.3 SLC6A4 PRODH POMC OXT MIR598 MAOA
31 endogenous depression 32.3 SLC6A4 POMC OXT MAOA LIPA HTR2C
32 avoidant personality disorder 32.2 WASF1 SLC6A4 MAOA
33 generalized anxiety disorder 32.1 SLC6A4 MAOA HTR2C HTR2A HTR1A COMT
34 personality disorder 32.1 SLC6A4 MAOA HTR2C HTR2A HTR1A CRH
35 acute stress disorder 32.1 SLC6A4 SERPINA3 POMC CRH BDNF
36 adjustment disorder 31.9 SLC6A4 HTR2A BDNF
37 alexithymia 31.9 SLC6A4 OXT HTR1A COMT
38 arteries, anomalies of 31.9 SERPINA3 MIRLET7D MIR9-1 H2AC18
39 post-traumatic stress disorder 31.8 SLC6A4 POMC MAOA HTR2A CRH COMT
40 panic disorder 31.8 SLC6A4 POMC MAOA HTR2C HTR2A HTR1A
41 physical disorder 31.8 PRODH MIR9-1 H2AC18
42 conduct disorder 31.8 SLC6A4 POMC MAOA COMT
43 alcohol dependence 31.7 SLC6A4 POMC OXT MAOA HTR2C HTR2A
44 agoraphobia 31.7 WASF1 SLC6A4 MAOA HTR2A HTR1A COMT
45 hypochondriasis 31.7 SLC6A4 POMC HTR2A HTR1A BDNF
46 substance abuse 31.6 WASF1 SLC6A4 SERPINA3 PRODH MAOA HTR2A
47 social phobia 31.6 WASF1 SLC6A4 SERPINA3 PRODH OXT MAOA
48 somatization disorder 31.6 SLC6A4 OXT HTR2A HTR1A CRH
49 alzheimer disease 31.5 SLC6A4 SERPINA3 OXT MAOA HTR2C HTR2A
50 drug dependence 31.5 SLC6A4 POMC CRH BDNF

Graphical network of the top 20 diseases related to Mental Depression:



Diseases related to Mental Depression
Sources

Symptoms & Phenotypes for Mental Depression

About this section

UMLS symptoms related to Mental Depression:


dejection emotional, depressed reaction, depression aggravated, affective symptoms, behavioral symptoms, schizophrenic language, depressive symptoms, depressed - symptom

MGI Mouse Phenotypes related to Mental Depression:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.1 BDNF COMT CRH DCTN1 HTR1A HTR2A
2 endocrine/exocrine gland MP:0005379 9.81 BDNF COMT CRH DPP4 HTR2A LIPA
3 homeostasis/metabolism MP:0005376 9.77 BDNF COMT CRH DCTN1 DPP4 HTR1A
4 nervous system MP:0003631 9.44 BDNF COMT CRH DCTN1 HTR1A HTR2C
Sources

Drugs & Therapeutics for Mental Depression

About this section

Drugs for Mental Depression (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 971)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
2
Reboxetine Approved, Experimental Phase 4 71620-89-8, 98769-81-4 123628 65856
3
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
4
Prucalopride Approved Phase 4 179474-81-8
5
Norethindrone Approved Phase 4 68-22-4 6230
6
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
7
Methimazole Approved Phase 4 60-56-0 1349907
8
Trimebutine Approved Phase 4 39133-31-8
9
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
10
Loperamide Approved Phase 4 53179-11-6 3955
11
Lactulose Approved Phase 4 4618-18-2 11333
12
Parecoxib Approved Phase 4 198470-84-7
13
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
14
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
15
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
16
Ethanol Approved Phase 4 64-17-5 702
17
Dextromethorphan Approved Phase 4 125-71-3 5360696 5362449
18
Lithium carbonate Approved Phase 4 554-13-2
19
Desipramine Approved, Investigational Phase 4 50-47-5 2995
20
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
21
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
22
Nortriptyline Approved Phase 4 72-69-5 4543
23
Zinc Approved, Investigational Phase 4 7440-66-6 32051
24
Simvastatin Approved Phase 4 79902-63-9 54454
25
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
26
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
27
Riluzole Approved, Investigational Phase 4 1744-22-5 5070
28
Memantine Approved, Investigational Phase 4 19982-08-2 4054
29
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
30
leucovorin Approved Phase 4 58-05-9 6006 143
31
Iloperidone Approved Phase 4 133454-47-4 71360
32
Calcium carbonate Approved, Investigational Phase 4 471-34-1
33
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
34
Levodopa Approved Phase 4 59-92-7 6047
35
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
36
Ribavirin Approved Phase 4 36791-04-5 37542
37
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
38
Isocarboxazid Approved Phase 4 59-63-2 3759
39
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
40
Protriptyline Approved Phase 4 438-60-8 4976
41
Trimipramine Approved Phase 4 739-71-9 5584 4055
42
Acetaminophen Approved Phase 4 103-90-2 1983
43
Zolpidem Approved Phase 4 82626-48-0 5732
44
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
45
Clonidine Approved Phase 4 4205-90-7 2803
46
Terazosin Approved Phase 4 63590-64-7 5401
47
Prazosin Approved Phase 4 19216-56-9 4893
48
Codeine Approved, Illicit Phase 4 76-57-3 5284371
49
Ranibizumab Approved Phase 4 347396-82-1 459903
50
Pravastatin Approved Phase 4 81093-37-0 54687

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Phase 4 Study of Escitalopram Treatment and Biomarkers in Major Depressive Disorder Unknown status NCT01997580 Phase 4 escitalopram
2 Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Unknown status NCT02294305 Phase 4 Vortioxetine;Placebo
3 The Effect and Reliability of Escitalopram in the Treatment of Adolescents With Major Depressive Disorder or Anxiety Disorders Unknown status NCT03122158 Phase 4 Escitalopram
4 Role of Inflammation Factors and Insulin Resistance in the Pathophysiology and Treatment Response of Major Depressive Disorder Unknown status NCT01699490 Phase 4 Fluoxetine + Valsartan;Fluoxetine + Placebo
5 Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder Unknown status NCT02051413 Phase 4 Venlafaxine extended release
6 Pharmacogenomics Studies of Antidepressants Unknown status NCT01204086 Phase 4 Venlafaxine;Fluoxetine
7 Phase 4 Study on the Effect of Partial Sleep Deprivation on Cognition and the IL-6-gp130-System in Individuals With Major Depression Unknown status NCT00291239 Phase 4
8 Clinical Trial of the Use of Ketamine in Treatment Resistant Depression Unknown status NCT02610712 Phase 4 Ketamine
9 Dose Response Effects of Estrogen Augmentation in Mood & Memory in Perimenopausal Depression Unknown status NCT00229450 Phase 4 estrogen
10 Randomized，Controlled and Open-label Study of Buspirone add-on Treatment in Patients With Major Depression Disorder Unknown status NCT02273154 Phase 4 Buspirone;Paroxetine
11 Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder Unknown status NCT01460212 Phase 4 SSRI antidepressants
12 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
13 Inflammatory Markers and Cognitive Function in Major Depression:a Pilot Study Unknown status NCT01391221 Phase 4 Duloxetine
14 A Dimensional Approach to Evaluate Reward Processing in Major Depressive Disorder Before and After Treatment With Desvenlafaxine Unknown status NCT02859103 Phase 4 Desvenlafaxine
15 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
16 Escitalopram and Sleep Architecture in Patients With Major Depressive Disorder Unknown status NCT00442481 Phase 4 Escitalopram
17 Duloxetine for the Treatment of Major Depression in Midlife Women: Effects on Brain Structure and Functioning, Mood, and Quality of Life Unknown status NCT00889369 Phase 4 Duloxetine
18 Escitalopram Treatment of Major Depression in Diabetes Mellitus: An Open Label Unknown status NCT00650897 Phase 4 Escitalopram
19 Turgut Ozal Medical Center Department of Anesthesiology and Reanimation Unknown status NCT02267980 Phase 4 Sevoflurane;Ketamine;Saline
20 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
21 A Comparative Trial of TMS Approaches to Treating Depression Unknown status NCT01906905 Phase 4
22 Hyperventilation and ECT Seizure Duration: Effects on Cerebral Oxygen Saturation, and Therapeutic Outcome With Comparisons Between Etomidate and Ketamine in Patients With Major Depressive Disorder Unknown status NCT02924090 Phase 4 Etomidate;Ketamine
23 White Matter Structure and Response to Treatment With Antidepressants: a Study of Desvenlafaxine in Major Depression. A Pilot Study Unknown status NCT01492621 Phase 4 Desvenlafaxine
24 Sequence Towards Remission in Depression Unknown status NCT01628783 Phase 4 escitalopram 10 mg;Placebo
25 Behandlung Von Leichten Und Unterschwelligen Depressionen. Eine Randomisierte, Kontrollierte Studie Zum Wirksamkeitsnachweis Eines Serotonin-Wiederaufnahme-Hemmers (SSRI), Einer Kognitiven Verhaltenstherapie Und Einer Freien Therapiewahl ("Treatment of Mild and Subthreshold Depressive Disorders". A Randomized, Controlled Trial on the Efficacy of a Serotonin-Reuptake-Inhibitor (SSRI), a Cognitive-Behavioral Therapy and of Free Choice Between SSRI and CBT") Unknown status NCT00226642 Phase 4 Sertralin;Placebo
26 A Randomised Trial Investigating the Cardiovascular Effects of Agomelatine and Escitalopram in Patients With Major Depressive Disorder. Unknown status NCT01483053 Phase 4 Agomelatine;Escitalopram
27 Algorithm Guided Treatment Strategies for Major Depressive Disorder Unknown status NCT01764867 Phase 4 Escitalopram;Mirtazapine;Fluoxetine;Citalopram;Escitalopram;Paroxetine;Sertraline;Fluvoxamine;Venlafaxine;Duloxetine;Mirtazapine;Bupropion;Trazodone
28 Evaluation of the Efficacy of Repetitive Transcranial Magnetic Stimulation on Cognitive, Anxiety and Depressive Symptoms in Patients Diagnosed With Major Depressive Disorder Unknown status NCT02213016 Phase 4
29 Neurochemical,Metabonomics and Neuroimaging Characterization of TCM Diagnostic Subtypes of Major Depression Disorder Unknown status NCT02346682 Phase 4 venlafaxine
30 A Randomized Controlled Study Comparing Fluoxetine With Bupropion for Impulsivity and Suicidality in Patients With Major Depressive Disorder and Comorbid Alcoholism (Abuse or Dependence) Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
31 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
32 THE AIUNI - Integral Assessment in Unipolar Depression Unknown status NCT02268487 Phase 4 Sertraline
33 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
34 The Effect of Quetiapine XR in Depressive Patients Showing Aberrant N100 Amplitude Slope Unknown status NCT01357967 Phase 4 SSRI monotherapy;Seroquel XR adjunctive
35 A Randomized Controlled Trial of Antidepressant Maintenance for Major Depression Following Mild Traumatic Brain Injury Unknown status NCT00162916 Phase 4 citalopram;Placebo
36 a Randomized, Double Blind, Placebo-controlled, Multicenter Clinical Trial of Efficacy and Safety of Shu Gan yi Yang Capsule in the Treatment of Depression Associated With Erectile Dysfunction (Stagnation of Liver qi and Kidney Deficiency) Unknown status NCT03290313 Phase 4 shu gan yi yang capsule;shu gan yi yang capsule simulation agent
37 Hippocampal Volume in Young Patients With Major Depression Before and After Combined Antidepressive Therapy - a Monocentric, Double-Blind, Placebo-Controlled Trial Unknown status NCT00150839 Phase 4 Mirtazapine;Venlafaxine
38 A Multicenter, Double Blind Trial to Compare the Efficacy and Safety of Escitalopram With Placebo in Patients With Acute Stroke for the Prevention of Poststroke Depression and Related Symptoms (Emotional Incontinence, Anger Proneness), and for Improvement of Neurologic, Cognitive Function and Quality of Life Unknown status NCT01278498 Phase 4 Escitalopram;sugar pill
39 Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial Unknown status NCT02777905 Phase 4
40 Treatment Prediction in Adolescent and Adult Depression Unknown status NCT00106197 Phase 4 Bupropion
41 Brain Mechanisms and Targeting Insomnia in Major Depression Unknown status NCT00628914 Phase 4 escitalopram and eszopiclone;Escitalopram, eszopiclone, and placebo;Escitalopram
42 TMSFOS: Preliminary Study to Investigate the Effect of rTMS and SSRI Antidepressants on Leukocyte Expression of the C-FOS and DUSP1 Genes in Patients Treated for Depression Unknown status NCT02042573 Phase 4 SSRI (SEROPLEX ou ZOLOFT)
43 Phase 4 Study of Vitamin D3 Supplementation for Outcomes in Patients With Unipolar Depression Unknown status NCT01390662 Phase 4
44 Antidepressant Treatments During Pregnancy and Lactation: Prediction of Drug Exposure Through Breastfeeding and Evaluation of Drug Effect on the Neonatal Adaptation and the Development of the Young Child Unknown status NCT01796132 Phase 4 SSRI/SNRI
45 Cymbalta for Depression as a Complication of Bereavement Unknown status NCT00658931 Phase 4 Drug treatment with Cymbalta
46 Collaborative Care for Depressed Elders in China Unknown status NCT01287494 Phase 4 Sertraline
47 Phase 3 Reboxetine Treatment in Depressed Children and Adolescents an 8-Week, Open Study Unknown status NCT00426946 Phase 4 Reboxetine
48 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
49 Randomized Evaluation of the Effectiveness of Lithium in Subjects With Treatment-Resistant Depression and Suicide Risk. An Independent, Pragmatic, Multicentre, Parallel-Group, Superiority Trial Unknown status NCT00927550 Phase 4 lithium;usual care
50 Double-Blind Randomised Investigation of Tibolone Alone or in Adjunct to Standard Antidepressant Treatment for Depression in Menopausal Women Unknown status NCT01470092 Phase 4 Tibolone

Search NIH Clinical Center for Mental Depression

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Alprazolam
Amitriptyline
Amitriptyline Hydrochloride
Amoxapine
Bupropion
Bupropion hydrobromide
Bupropion Hydrochloride
Buspirone
buspirone hydrochloride
Citalopram
Citalopram hydrobromide
Clomipramine
Clomipramine Hydrochloride
Desipramine
Desipramine Hydrochloride
Doxepin
Doxepin Hydrochloride
Escitalopram
Escitalopram oxalate
Fluoxetine
Fluoxetine Hydrochloride
Fluvoxamine
Fluvoxamine Maleate
HYPERICUM PERFORATUM (ST. JOHN'S WORT)
Imipramine
Imipramine Hydrochloride
Imipramine pamoate
Isocarboxazid
Isoflurane
Kava preparation
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Lorazepam
Maprotiline
Maprotiline Hydrochloride
Methylphenidate
Methylphenidate Hydrochloride
Mirtazapine
nefazodone
Nortriptyline
Nortriptyline Hydrochloride
Paroxetine
Paroxetine Hydrochloride
Phenelzine
Phenelzine Sulfate
Pramipexole
Pramipexole dihydrochloride
Protriptyline
Protriptyline Hydrochloride
Selegiline
selegiline hydrochloride
Sertraline
Sertraline Hydrochloride
Temazepam
Tranylcypromine
Tranylcypromine sulfate
Trazodone
Trazodone Hydrochloride
Tricyclic Antidepressant [EPC]
Trimipramine
Trimipramine Maleate
venlafaxine
Venlafaxine hydrochloride

Cochrane evidence based reviews: depression

Sources

Genetic Tests for Mental Depression

About this section
Sources

Anatomical Context for Mental Depression

About this section

MalaCards organs/tissues related to Mental Depression:

40
Brain, Heart, Testes, Breast, Cortex, Lung, Prefrontal Cortex
Sources

Publications for Mental Depression

About this section

Articles related to Mental Depression:

(show top 50) (show all 26910)
# Title Authors PMID Year
1
Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. 61
31634515 2020
2
Seasonal affective disorder and seasonal changes in weight and sleep duration are inversely associated with plasma adiponectin levels. 61
31981963 2020
3
Brain Changes Induced by Electroconvulsive Therapy Are Broadly Distributed. 61
31561859 2020
4
Antidepressant Efficacy of Prolonged Intermittent Theta Burst Stimulation Monotherapy for Recurrent Depression and Comparison of Methods for Coil Positioning: A Randomized, Double-Blind, Sham-Controlled Study. 61
31563272 2020
5
Toward an assessment of escape/avoidance coping in depression. 61
31739002 2020
6
Effects of desvenlafaxine versus placebo on MDD symptom clusters: A pooled analysis. 61
31913085 2020
7
Fluoxetine improves behavioural deficits induced by chronic alcohol treatment by alleviating RNA editing of 5-HT2C receptors. 61
31968217 2020
8
Classical Human Leukocyte Antigen Alleles and C4 Haplotypes Are Not Significantly Associated With Depression. 61
31570195 2020
9
Involvement of CX3CL1/CX3CR1 in depression and cognitive impairment induced by chronic unpredictable stress and relevant underlying mechanism. 61
31765724 2020
10
Developing Predictive Biomarkers Goes Alongside Diagnostic Biotypes in Major Depressive Disorder. 61
32029074 2020
11
Seeking for potential pathogenic genes of major depressive disorder in the Gene Expression Omnibus database. 61
31889427 2020
12
Connectivity of the Cognitive Control Network During Response Inhibition as a Predictive and Response Biomarker in Major Depression: Evidence From a Randomized Clinical Trial. 61
31601424 2020
13
Mixed Features in Depression: The Unmet Needs of Diagnostic and Statistical Manual of Mental Disorders Fifth Edition. 61
32008688 2020
14
Genetics of resilience: Implications from genome-wide association studies and candidate genes of the stress response system in posttraumatic stress disorder and depression. 61
31583809 2020
15
The influence of posttraumatic stress disorder and recurrent major depression on risk-taking propensity following trauma script exposure among patients with substance use disorders. 61
31775063 2020
16
Rumination network dysfunction in major depression: A brain connectome study. 61
31734293 2020
17
Pigment epithelium-derived factor alleviates depressive-like behaviors in mice by modulating adult hippocampal synaptic growth and Wnt pathway. 61
31676463 2020
18
Abnormal functional connectivity strength in first-episode, drug-naïve adult patients with major depressive disorder. 61
31499128 2020
19
Approach-Avoidance Conflict in Major Depressive Disorder: Congruent Neural Findings in Humans and Nonhuman Primates. 61
31672243 2020
20
Elated or sad mood induction affects the attention of patients with a bipolar disorder less than that of patients with a depressive disorder. 61
31707921 2020
21
Cell Type-Specific Methylome-wide Association Studies Implicate Neurotrophin and Innate Immune Signaling in Major Depressive Disorder. 61
31889537 2020
22
Dorsomedial prefrontal cortex repetitive transcranial magnetic stimulation for treatment-refractory major depressive disorder: A three-arm, blinded, randomized controlled trial. 61
31711880 2020
23
Large-scale dynamic causal modeling of major depressive disorder based on resting-state functional magnetic resonance imaging. 61
32026598 2020
24
Structural alterations associated with suicide attempts in major depressive disorder and bipolar disorder: A diffusion tensor imaging study. 61
31778758 2020
25
Suicidality, Depression, and the FDA: Health Inequities and the Ethical Conduct of Research. 61
32023368 2020
26
Maintaining Rapid Antidepressant Effects Following Ketamine Infusion: A Major Unmet Need. 61
32023369 2020
27
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram. 61
31010445 2020
28
Nurse-Delivered Cognitive Behavioral Therapy for Adherence and Depression Among People Living With HIV (the Ziphamandla Study): Protocol for a Randomized Controlled Trial. 61
32012114 2020
29
Association of poorer dietary quality and higher dietary inflammation with greater symptom severity in depressed individuals with appetite loss. 61
31818803 2020
30
Screening and Counseling Adolescents and Young Adults: A Framework for Comprehensive Care. 61
32003959 2020
31
Use of home health and other healthcare delivery pathways among privately insured patients with and without treatment-resistant depression. 61
31985319 2020
32
Association Analysis Between the rs1899663 Polymorphism of HOTAIR and Risk of Psychiatric Conditions in an Iranian Population. 61
32036581 2020
33
Machine Learning Identifies Large-Scale Reward-Related Activity Modulated by Dopaminergic Enhancement in Major Depression. 61
31784354 2020
34
A pharmacogenetic risk score for the evaluation of major depression severity under treatment with antidepressants. 61
31617956 2020
35
Impact of Wartime Stress Exposures and Mental Health on Later-Life Functioning and Disability in Vietnam-Era Women Veterans: Findings From the Health of Vietnam-Era Women's Study. 61
31714370 2020
36
Differences in the immune-inflammatory profiles of unipolar and bipolar depression. 61
31693974 2020
37
Randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder. 61
31725942 2020
38
Effect of probiotic and prebiotic versus placebo on appetite in patients with major depressive disorder: post hoc analysis of a randomised clinical trial. 61
31338923 2020
39
Ketamine exerts a protective role in a cell-based model of major depressive disorder via the inhibition of apoptosis and inflammation and activation of the Krebs cycle. 61
31215856 2020
40
Prevalence and clinical correlates of psychotic depression in first-episode and drug-naïve outpatients with major depressive disorder in a Chinese Han population. 61
31759662 2020
41
Prevalence and clinical correlates of subclinical hypothyroidism in first-episode drug-naive patients with major depressive disorder in a large sample of Chinese. 61
31759671 2020
42
A Case Report of Transcranial Magnetic Stimulation-Related Seizure in a Young Patient With Major Depressive Disorder Receiving Accelerated Transcranial Magnetic Stimulation. 61
32040022 2020
43
Medial temporal lobe volumes in late-life depression: effects of age and vascular risk factors. 61
30251182 2020
44
Shared and specific functional connectivity alterations in unmedicated bipolar and major depressive disorders based on the triple-network model. 61
30382529 2020
45
Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. 61
31791675 2020
46
Alexithymia as a possible specifier of adverse outcomes: Clinical correlates in euthymic unipolar individuals. 61
31969274 2020
47
Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis. 61
31427752 2020
48
Evaluation of anti-depressant effects of phthalazinone-based triple-acting small molecules against 5-HT2A, 5-HT2C, and the serotonin transporter. 61
31889666 2020
49
Major depressive disorder in Chinese persons with speech disability: High rates of prevalence and perceived need for mental health care but extremely low rate of use of mental health services. 61
31818785 2020
50
Re: "The Impact of Placebo Response Rates on Clinical Trial Outcome: A Systematic Review and Meta-Analysis of Antidepressants in Children and Adolescents with Major Depressive Disorder" by Li Y, Huang J, He Y, Yang J, Lv Y, Liu H, Liang L, Zheng Q, and Li L (J Child Adolesc Psychopharmacol 29:712-720, 2019). 61
31603715 2020
Sources

Variations for Mental Depression

About this section
Sources

Expression for Mental Depression

About this section
Search GEO for disease gene expression data for Mental Depression.
Sources

Pathways for Mental Depression

About this section

Pathways related to Mental Depression according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
cAMP signaling pathway 36
12.04 POMC OXT HTR1A BDNF
2
Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways 1
11.86 SLC6A4 MAOA HTR2A HTR1A BDNF
3
Serotonergic synapse 36
11.61 SLC6A4 MAOA HTR2C HTR2A HTR1A
4
Neurotransmitter Clearance In The Synaptic Cleft 65
Show member pathways
 10.91 SLC6A4 MAOA COMT
5
noradrenaline and adrenaline degradation 1
Show member pathways
 10.63 MAOA COMT
6
Methylphenidate Pathway, Pharmacodynamics 60
Show member pathways
 10.62 SLC6A4 MAOA HTR1A COMT
7
Dopamine metabolism 1
10.58 MAOA COMT
8
Selective Serotonin Reuptake Inhibitor Pathway, Pharmacodynamics 60
10.47 SLC6A4 MAOA HTR2C HTR2A HTR1A
9
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
10.21 POMC CRH
Sources

GO Terms for Mental Depression

About this section

Cellular components related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendrite GO:0030425 9.02 HTR2C HTR2A HTR1A COMT BDNF

Biological processes related to Mental Depression according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.86 HTR2C HTR2A HTR1A CRH
2 response to drug GO:0042493 9.8 SLC6A4 HTR2C HTR2A CRH COMT
3 female pregnancy GO:0007565 9.76 OXT CRH COMT
4 G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.69 HTR2C HTR2A HTR1A
5 locomotory exploration behavior GO:0035641 9.58 DPP4 CRH
6 sleep GO:0030431 9.57 OXT HTR2A
7 neurotransmitter catabolic process GO:0042135 9.55 MAOA COMT
8 catecholamine metabolic process GO:0006584 9.54 MAOA COMT
9 behavioral fear response GO:0001662 9.54 HTR2C HTR1A DPP4
10 dopamine catabolic process GO:0042420 9.52 MAOA COMT
11 regulation of appetite GO:0032098 9.49 POMC HTR2C
12 sperm ejaculation GO:0042713 9.48 SLC6A4 OXT
13 response to ether GO:0045472 9.46 OXT CRH
14 memory GO:0007613 9.46 SLC6A4 OXT HTR2A BDNF
15 positive regulation of phosphatidylinositol biosynthetic process GO:0010513 9.43 HTR2C HTR2A
16 regulation of serotonin secretion GO:0014062 9.32 HTR1A CRH
17 phospholipase C-activating serotonin receptor signaling pathway GO:0007208 9.26 HTR2C HTR2A
18 behavior GO:0007610 9.13 HTR2C HTR2A HTR1A
19 serotonin receptor signaling pathway GO:0007210 8.8 HTR2C HTR2A HTR1A

Molecular functions related to Mental Depression according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neurotransmitter receptor activity GO:0030594 9.43 HTR2C HTR2A HTR1A
2 G protein-coupled serotonin receptor activity GO:0004993 9.33 HTR2C HTR2A HTR1A
3 1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding GO:0071886 8.96 HTR2C HTR2A
4 serotonin binding GO:0051378 8.92 SLC6A4 HTR2C HTR2A HTR1A
Sources

Sources for Mental Depression

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....